#China #Shanghai #Serplulimab #Henlius Biotech #HERCESSI

Overview

Henlius Biotech Inc. recently disclosed its annual financial results for the year ending December 31, 2025, reflecting considerable advancements in both revenue and net profits. This report follows a trajectory of consistent growth and innovation, signaling a bright future for the company as it embraces a robust global strategy.

During the 2025 fiscal year, Henlius achieved a substantial revenue of RMB 6.6666 billion, marking a 16.5% increase compared to the previous year. Their net profit also soared to RMB 0.8270 billion, illustrating a strong financial performance. This marked the third consecutive year of profitability for Henlius since its transition to full-year profitability in 2023. Additionally, the company noted a remarkable 35.4% increase in research and development investments, totaling RMB 2.4919 billion. This focus on innovation is expected to fortify Henlius' ambitious pipeline and product offerings moving forward.

International Expansion

One of the most noteworthy aspects of Henlius' performance is its strategic expansion in global markets. The company's total product revenue climbed to RMB 5.7746 billion from international operations, realizing a 17.0% growth compared to the prior year. Central to this growth is the revenue derived from the core products, especially serplulimab, branded Hetronifly® in Europe, and HANQUYOU, which has high demand across various territories. Specifically, Henlius' ex-China business saw revenues cross RMB 200 million in 2025, amounting to a twofold increase from the previous year. Notably, the company has secured approval for ten products across 60 global regions, thus extending its reach to over one million patients worldwide.

Leadership and Vision

Dr. Jason Zhu, the current CEO of Henlius, emphasized the significance of 2025 as a transformative year for the company. He acknowledged the advancements in their innovation pipeline, which reflects their dedication to meeting essential clinical needs. Looking toward the future, Dr. Zhu articulated a vision where Henlius aims to leverage its integrated business model to enhance patient access to high-quality biologics globally. The company’s commitment to bio-pharmaceutical innovation remains its core principle as it tackles the intricate needs of patients.

Product Growth and Performance

In 2025, Henlius recorded exceptionally high sales in its flagship product, serplulimab, achieving a global sales revenue of RMB 1.4926 billion—an impressive 13.7% growth year on year. The expanding approvals in Europe and various emerging markets for treating extensive-stage small cell lung cancer (SCLC) solidify serplulimab's positioning as a vital therapeutic option. Furthermore, it has been integrated into public reimbursement systems across multiple European nations.

The breast cancer treatment portfolio also saw substantial growth. Revenue from related products reached RMB 3.2675 billion. The core product in this segment, HANQUYOU, generated RMB 2.9645 billion in sales, underlining its strong market presence in over 50 countries. This growth is complemented by the performance of emerging products, establishing a well-rounded resource chain that enhances patient care.

Sustaining Innovation and Pipeline Growth

Henlius continues to strengthen its innovation capacity through a multilayered technology ecosystem, including advanced R&D platforms. The company aims to maintain a competitive edge in the global biopharmaceutical arena by continuously expanding its product pipeline, regulatory approvals, and strategic partnerships. Notably, the collaboration with prominent international partners has paved the way for more licensing agreements, thereby extending Henlius' global footprint.

As part of its commitment to patient welfare, Henlius has initiated rigorous clinical studies across 30 countries to expand its present therapeutic offerings. Maintaining a robust commitment to research and development, Henlius anticipates more than 20 product approvals globally by 2030, further solidifying its presence in the industry.

Conclusion

In summary, Henlius' remarkable 2025 performance highlights its sustained revenue and profit growth, alongside its unwavering dedication to innovation and patient care. The company's global aspirations and innovative strategies position it favorably as a leading biopharmaceutical entity, not only in China but increasingly on the international stage. As Henlius continues to develop and launch high-quality biologic therapies, it strikes a promising balance between addressing critical patient needs and pushing the frontiers of pharmaceutical science.